Can a CT scan predict who will benefit from lung cancer chemoimmunotherapy?
NCT ID NCT07559123
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether features on CT scans can predict how well non-small cell lung cancer responds to chemoimmunotherapy given before surgery. Researchers will compare CT images taken before and after treatment with the actual results from surgery. The goal is to develop a noninvasive tool to guide treatment decisions and reduce unnecessary side effects.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- High-resolution deep learning-based CT reconstruction
- What this could lead to
- If successful, this could lead to a noninvasive way to identify which lung cancer patients are most likely to benefit from chemoimmunotherapy before surgery, helping tailor treatment and avoid unnecessary side effects.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly change patient care yet. The imaging biomarkers may not prove accurate enough in larger or more diverse groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 150 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2026
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population will include adult patients with resectable non-small cell lung cancer of stage IIIA or lower who are scheduled to receive neoadjuvant chemoimmunotherapy before surgery at Samsung Medical Center. Participants will be enrolled prospectively after providing written informed consent. Treatment decisions, including the use of neoadjuvant chemoimmunotherapy and surgery, will be made according to standard clinical practice and will not be assigned by the investigators. Participants will undergo chest computed tomography before neoadjuvant chemoimmunotherapy and before surgery as part of the study protocol. Imaging, clinical, molecular, and pathologic data will be collected to evaluate computed tomography-based imaging biomarkers associated with treatment response, pathologic response, treatment-related pneumonitis, and clinical outcomes.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age: 18 years or older. * Diagnosis: Histologically or cytologically confirmed non-small cell lung cancer (NSCLC). * Staging: Resectable NSCLC of stage IIIA or lower. * Treatment Plan: Planned to receive neoadjuvant chemoimmunotherapy before surgery according to standard clinical practice. * Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Informed Consent: Able and willing to provide written informed consent after receiving a detailed explanation of the study. Exclusion Criteria: * No Measurable Lesion: Participants must have at least one measurable lesion (\>= 10 mm on spiral/multidetector computed tomography). * Prior Malignancy: History of another malignancy within 5 years before enrollment (excluding adequately treated basal cell skin carcinoma or cervical carcinoma in situ). * Neurological/Psychiatric Conditions: History of clinically significant uncontrolled seizures, CNS disease, or psychiatric disorders that may interfere with study participation or consent. * Contrast Allergy: History of severe allergic reaction to iodinated CT contrast media. * Renal Impairment: Acute renal failure or moderate to severe renal impairment (CrCl \< 45 mL/min/1.73 m² or serum creatinine \> 1.5x upper limit of normal). * Recent Surgery: Major surgery within 4 weeks of enrollment or incomplete recovery from major surgery. * Pregnancy/Nursing: Currently pregnant or breastfeeding; women of childbearing potential without a negative baseline pregnancy test. * Contraception: Men or women of childbearing potential unwilling to use appropriate contraception during the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CT are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Samsung Medical Center
RECRUITINGSeoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new targeted drug shrink lung tumors?
- Can a targeted drug delivery system shrink lung tumors?
- Can a new drug combo revive the immune System's attack on resistant cancers?
- Can a cell therapy shrink Hard-to-Treat lung tumors?
- Can a nebulized biologic fight lung cancer from the inside out?
- Sharper CT scans may solve a lung disease diagnostic puzzle